Efficacy and Safety of IL-17 and JAK Inhibitors in Ankylosing Spondylitis: A Systematic Review and Network Meta-Analysis

塞库金单抗 医学 托法替尼 伊克泽珠单抗 强直性脊柱炎 安慰剂 内科学 随机对照试验 荟萃分析 银屑病性关节炎 类风湿性关节炎 替代医学 病理
作者
Xiaojuan Zhao,Menghao Li,Xinhui Zhang,Yunfei Tian,Dan Li,Yongjing Wang,Yonghong Zhao,Qianying Li,Y.-F. Qi,Xiuju Liu
出处
期刊:International Archives of Allergy and Immunology [S. Karger AG]
卷期号:: 1-18
标识
DOI:10.1159/000544752
摘要

Objective: The aim of this study was to compare the clinical efficacy and safety of interleukin-17 inhibitors and Janus kinase inhibitors in the treatment of ankylosing spondylitis based on a network meta-analysis. Methods: According to the search strategy, systematic retrievals were conducted in PubMed, Embase, Web of Science, the Cochrane Register of Clinical Trials, Scopus, and website ClinicalTrials.gov, from the establishment to December 8, 2023. Randomized controlled trials (RCTs) of interleukin-17 inhibitors and Janus kinase inhibitors for the treatment of ankylosing spondylitis were selected according to the inclusion and exclusion criteria. The included studies were evaluated for quality using the Cochrane Risk of Bias Assessment Tool, and data were statistically analyzed using Software Stata 16.0, to compare the effectiveness and safety differences in all interventions. Results: A total of 18 RCTs involving 3968 subjects were included in this study. The interventions were ranked from best to worst in terms of ASAS20: netakimab 120 mg > filgotinib 200 mg > tofacitinib 5 mg> brodalumab 210 mg >upadacitinib 15 mg >bimekizumab 160 mg > secukinumab 300 mg> ixekizumab 80 mg Q4W > secukinumab 150 mg > secukinumab 150 mg no LD> placebo, netakimab 120 mg outperformed all other interventions and the difference was statistically significant. The interventions were ranked from best to worst in terms of ASAS40: netakimab 120 mg > tofacitinib 5 mg > secukinumab 150 mg > secukinumab 300 mg > upadacitinib 15 mg > bimekizumab 160 mg> ixekizumab 80 mg Q4W > filgotinib 200 mg > brodalumab 210 mg > secukinumab 150 mg no LD > placebo, netakimab 120 mg outperformed all other interventions and was statistically significant (except the intervention of filgotinib 200 mg). In terms of AEs and SAEs, there was no statistical significance among all interventions. Conclusions: The results of the network meta-analysis showed that netakimab 120mg ranked relatively high in outcome of ASAS20 and ASAS40. All treatments with IL-17 and JAK inhibitors were generally safe and well tolerated. However, the two included netakimab clinical studies may have limitations. Therefore, the therapeutic agents should be carefully selected in clinical treatment. Moreover, the efficacy and safety of netakimab remain to be further analyzed in studies with larger sample sizes and longer follow-up times.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
爆米花应助快乐的板凳采纳,获得10
1秒前
3秒前
carbon完成签到,获得积分10
4秒前
狮子沟核聚变骡子完成签到 ,获得积分10
5秒前
Lu发布了新的文献求助10
6秒前
6秒前
7秒前
8秒前
8秒前
天才小熊猫完成签到,获得积分10
12秒前
李w完成签到,获得积分10
17秒前
17秒前
懂得珍惜发布了新的文献求助10
21秒前
冬枣枣发布了新的文献求助10
23秒前
qkl完成签到,获得积分20
24秒前
tjzbw完成签到,获得积分10
24秒前
26秒前
gonna完成签到,获得积分10
27秒前
Akim应助tanjuan采纳,获得10
27秒前
852应助人机灵采纳,获得10
27秒前
科研通AI5应助Martin采纳,获得10
29秒前
懂得珍惜完成签到,获得积分20
29秒前
kearthy完成签到,获得积分10
30秒前
qiqi发布了新的文献求助10
30秒前
30秒前
顾矜应助qkl采纳,获得10
30秒前
称心的士晋应助Robin采纳,获得10
31秒前
31秒前
桐桐应助范小楠采纳,获得10
32秒前
852应助妥妥酱采纳,获得10
33秒前
共享精神应助瓶子采纳,获得10
33秒前
逝者如斯只是看着完成签到,获得积分10
34秒前
楼亦玉完成签到,获得积分10
34秒前
34秒前
35秒前
小鞋发布了新的文献求助10
35秒前
CountFCL发布了新的文献求助10
35秒前
李振博完成签到 ,获得积分10
37秒前
39秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
England and the Discovery of America, 1481-1620 600
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3572505
求助须知:如何正确求助?哪些是违规求助? 3142644
关于积分的说明 9448520
捐赠科研通 2844063
什么是DOI,文献DOI怎么找? 1563224
邀请新用户注册赠送积分活动 731661
科研通“疑难数据库(出版商)”最低求助积分说明 718667